Advertisement
ACB vs MEDIF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Buy and MEDIF is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 0 FA rating(s) are green whileMEDIF’s FA Score has 0 green FA rating(s).
- ACB’s FA Score: 0 green, 5 red.
- MEDIF’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 3 TA indicator(s) are bullish while MEDIF’s TA Score has 3 bullish TA indicator(s).
- ACB’s TA Score: 3 bullish, 5 bearish.
- MEDIF’s TA Score: 3 bullish, 2 bearish.
Price Growth
ACB (@Pharmaceuticals: Other) experienced а -6.31% price change this week, while MEDIF (@Pharmaceuticals: Other) price change was +4.29% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.43%. For the same industry, the average monthly price growth was +7.35%, and the average quarterly price growth was +81.90%.
Reported Earning Dates
ACB is expected to report earnings on Nov 06, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+2.43% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ACB | MEDIF | ACB / MEDIF | |
| Capitalization | 239M | 19.1M | 1,251% |
| EBITDA | -1.64B | -41.42M | 3,952% |
| Gain YTD | -0.353 | 29.540 | -1% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 212M | 22.2M | 955% |
| Total Cash | 149M | 20.2M | 738% |
| Total Debt | 103M | 218K | 47,248% |
ACB | MEDIF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 95 | |
PRICE GROWTH RATING 1..100 | 62 | 58 | |
P/E GROWTH RATING 1..100 | 92 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACB's Valuation (57) in the Pharmaceuticals Other industry is in the same range as MEDIF (89) in the null industry. This means that ACB’s stock grew similarly to MEDIF’s over the last 12 months.
ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MEDIF (100) in the null industry. This means that ACB’s stock grew similarly to MEDIF’s over the last 12 months.
ACB's SMR Rating (90) in the Pharmaceuticals Other industry is in the same range as MEDIF (95) in the null industry. This means that ACB’s stock grew similarly to MEDIF’s over the last 12 months.
MEDIF's Price Growth Rating (58) in the null industry is in the same range as ACB (62) in the Pharmaceuticals Other industry. This means that MEDIF’s stock grew similarly to ACB’s over the last 12 months.
ACB's P/E Growth Rating (92) in the Pharmaceuticals Other industry is in the same range as MEDIF (100) in the null industry. This means that ACB’s stock grew similarly to MEDIF’s over the last 12 months.
| ACB | MEDIF | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Advances ODDS (%) | 4 days ago 77% | 3 days ago 84% |
| Declines ODDS (%) | 2 days ago 88% | 9 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | N/A |
| Aroon ODDS (%) | 2 days ago 80% | N/A |
Advertisement
ACB and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACB has been loosely correlated with SNDL. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To ACB | 1D Price Change % | ||
|---|---|---|---|---|
| ACB | 100% | -7.93% | ||
| SNDL - ACB | 65% Loosely correlated | +1.81% | ||
| CGC - ACB | 64% Loosely correlated | -2.78% | ||
| OGI - ACB | 59% Loosely correlated | N/A | ||
| CRON - ACB | 56% Loosely correlated | +1.94% | ||
| TLRY - ACB | 54% Loosely correlated | -2.93% | ||
More | ||||